-
Nov 17, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Jack Khouri, MD: So, Greg, we seem like a big fan of this. Craig Cole, MD: I didn’t want to tell you. But the patients that I had on [the trial] are what make me a fan. The patients I had when we had to discontinue in November had to stop therapy and remain in very good, or even CRs [complete responses] for months and months. I think the longest one is a patient I still have from November when I discontinued, and she’s still in a CR.
-
Nov 10, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Judy Schreiber, PhD, RN: We’ll go on to the next presentation, which will be Dr [Craig] Cole presenting on the DREAMM-3 study [NCT04162210]. Craig Cole, MD: Thanks, and I was just an investigator on the DREAMM-6 study [NCT03544281]. I want to thank everyone for inviting me, and Dr Weisel for sharing her slides with me. So belantamab mafodotin or Blenrep is a humanized anti-BCMA conjugated antibody.
-
Nov 10, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Craig Cole, MD: Faiz, where do you think you’d use a regimen like this? I think this was a French study done a few years ago. How do you think this fits into the landscape these days? Faiz Anwer, MD, FACP: I think this fits in with the more frail or [older] patients. A significant number of patients are not close to a major academic center. There’s a significant number of patients who don’t want to travel so frequently.
-
Nov 3, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
-
Oct 27, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
-
Oct 20, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
-
Oct 20, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Judy Schreiber, PhD, RN: Over to our Cleveland Clinic [team], if you have any comments or questions, or any statements you want to make related to this abstract, please feel free. Faiz Anwer, MD: I just have a question. …Who is the ideal patient eligible for this combination therapy?
-
Oct 20, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Judy Schreiber, PhD, RN: Let’s move on to the next abstract that will be presented by Dr Khouri, which is related to the CARTITUDE-4 study [NCT04181827]. Jack Khouri, MD: There are more exciting data on cilta-cel [ciltacabtagene autoleucel]. I’ll be presenting the results of the phase 3 CARTITUDE-4 study of cilta-cel vs standard of care with PVd [pomalidomide, bortezomib, dexamethasone] or DPd [daratumumab, pomalidomide, dexamethasone] in lenalidomide-refractory multiple myeloma [MM].
-
Oct 13, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
